Rigel Pharmaceuticals (RIGL) Change in Receivables (2014 - 2026)

Rigel Pharmaceuticals' Change in Receivables history runs 12 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 2573.53% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was $8.4 million, a 40.16% decrease from a year earlier, with the FY2025 full-year figure at $10.1 million, down 8.29% from the prior year.
• Change in Receivables declined to -$1.8 million in Q1 2026 per RIGL's latest filing, from $5.8 million in the prior quarter.
• Across five years, Change in Receivables topped out at $24.8 million in Q4 2022 and bottomed at -$11.0 million in Q1 2023.
• The 5-year median for Change in Receivables is $1.4 million (2024), against an average of $2.0 million.
• Across the five-year window, Change in Receivables jumped 5054.89% in 2022 and tumbled 4621.55% in 2023, its largest moves.
• Year by year, Change in Receivables stood at $24.8 million in 2022, then slumped by 71.75% to $7.0 million in 2023, then soared by 57.62% to $11.0 million in 2024, then plunged by 47.12% to $5.8 million in 2025, then slumped by 131.14% to -$1.8 million in 2026.
• Per Business Quant, the three latest RIGL Change in Receivables figures stand at -$1.8 million (Q1 2026), $5.8 million (Q4 2025), and $6.0 million (Q3 2025).